Coming of Age in Neoliberal New York

Thirty years of neoliberal policies have left New York a divided city, with ever-rising rates of income inequality and widening social disparity. Structural transformations associated with global capitalism have led to divergent experiences for male and female youth coming of age in the 21st century. Girls are experiencing greater social integration and social mobility whereas, boys are facing social exclusion and limited opportunities. As young men precariously forge new transitions to adulthood, young women are constructed as ideal flexible subjects, benefiting from feminist achievements, and advancing in the new service economy. Yet in reality, girls continue to face gendered base violence, sexism, and burdens of responsibilities. Through this lens, I examine how gender operates as an organizing principle in young people\u27s lives today in the Lower East Side (LES) of New York City. This study also documents how people create cultural alternatives that reflect their values and progressive politics and analyzes how this has been down in the past. It offers an organizational case study of The Lower Eastside Girls Club in an effort to increase our understanding of the history and significance of a successful struggle to educate, employ, and carve out a safe space for women and girls in neoliberal New York. It documents how the Girls Club builds upon a legacy of grassroots initiatives in the LES, including the settlement house movement of the Progressive Era and Mobilization for Youth of the 1960\u27s. This study asks: what should an education accomplish in a democracy? (Giroux 2013) It examines the limitations of the Girls Club\u27s engaged practice of uplift and empowerment in relation to its progressive politics and critical pedagogy. I suggest that education is a terrain in the right to the city (Lefebvre 1968), and that the Girls Club, in constructing alternative models of education and community engagement, is locally engaging in a broader struggle for social justice, albeit with limited success. This study concludes with an analysis of Girls Club\u27s efforts to push forth a community-led development model that puts women and youth at the center, melding the politics of Jane Addams and Jane Jacobs and offering an alternative urban vision

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

Purpose: Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an anti-HER2 antibody, in trastuzumab-resistant HER2+ cell lines. This open-label, single-arm, phase II study evaluated the efficacy and safety of enzalutamide, an AR-signaling inhibitor, in patients with advanced HER2+ AR+ breast cancer previously treated with trastuzumab. Methods: Eligible patients had measurable or non-measurable evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Eastern Cooperative Oncology Group status 64 1, no history of brain metastases, and previously received 65 1 anti-HER2 regimen for advanced disease. Patients received 160\ua0mg oral enzalutamide daily and 6\ua0mg/kg intravenous trastuzumab every 21\ua0days until disease progression or unacceptable toxicity. Primary end point was clinical benefit rate at 24\ua0weeks (CBR24); secondary end points included progression-free survival (PFS) and safety. Results: Overall, 103\ua0women were enrolled [median age 60\ua0years (range 34\u201383)]; 62% had received 65 3\ua0lines of prior anti-HER2 therapy. CBR24, comprising patients with confirmed partial responses (5%) and durable stable disease at 24\ua0weeks (19%), was 24% in the efficacy evaluable set (n = 89). CBR24 did not seem related to AR-expression levels or hormone receptor status. Median PFS was 3.4\ua0months (95% confidence interval 2.0\u20133.8). Overall, 97 (94%) patients experienced treatment-emergent adverse events (TEAEs), with fatigue most common (34%). Dyspnea (4%) and malignant neoplasm progression (3%) were the only TEAEs grade 65 3 reported in 65 3\ua0patients. 22 patients (21%) reported serious TEAEs. Four patients (4%) experienced fatal, non-drug-related TEAEs. Conclusions: Enzalutamide plus trastuzumab was well tolerated, and a subset of patients in this heavily pretreated population had durable disease control. Determination of biomarkers is needed to identify patients most likely to benefit from this combination. ClinicalTrials.gov number: NCT0209196